Safty research of intraoperative intraperitoneal chemotherapy with raltitrexed for advanced colorectal cancer

doi:10.3760/cma.j.issn.1673-422X.2016.06.005

Abstract

Abstract: Objective To investigate the intraoperative intraperitoneal chemotherapy security with raltitrexed in advanced colorectal cancer surgical operation. MethodsSixty patients with colorectal cancer undergone surgery were randomly divided into trial group (n=30) and control group (n=30) according to the random number table method. The trial group was given surgical operation plus with intraperitoneal chemotherapy with raltitrexed. The control group was given surgical operation plus with intraperitoneal saline perfusion. Theroutine blood test, liver and kidney functions, toxic side effects and complications in two groups before and after surgery were investigated. ResultsThe white blood cells in trial group before and after surgery was (6.36±2.63)×109/L vs. (8.20±2.08)×109/L, with statistically significant difference (t=3.06, P＜0.05). The ratio of absolute neutrophil count in trial group before and after surgery was 65.17%±10.36% vs.72.21%±10.53% (t=3.22, P＜0.05).The platelets in trial group before and after surgery was (261.03±84.74)×109/L vs.(228.47±58.69)×109/L (t=2.07, P＜0.05). The white blood cells, the ratio of absolute neutrophil count and the platelets after surgery had no statistically significant differences between the two groups (P>0.05). The trial group had higher 1, 2 level vomiting (60.00% vs. 23.33%; χ2=8.30, P<0.05), and nausea (30.00% vs. 6.67%; χ2=5.46, P<0.05) incidence rates, but there was no statistically significant difference in other toxic side effects (P>0.05). The major complications post operation included intestinal obstruction, incision infection, abdominal cavity bleeding, and anastomotic fistula. There were equivalent complications in two groups (6.67% vs. 3.33%, χ2=0.35, P>0.05; 10.00% vs. 6.67%, χ2=0.22, P>0.05; 0 vs. 0；3.33% vs. 0, P>0.05). ConclusionFor patients with advanced colorectal cancer, intraoperative intraperitoneal chemotherapy with raltitrexed is safe and feasible, and the adverse reactions can be tolerated without increasing postoperative complications.

Key words: Colorectal neoplasms, Raltitrexed, Abdominal cavity, Drug therapy

Li Shuyuan, Zhang Qinghuai, Geng Shu′an, Gao Hao, Yang Jingwen. Safty research of intraoperative intraperitoneal chemotherapy with raltitrexed for advanced colorectal cancer[J]. Journal of International Oncology, 2016, 43(6): 420-423.

References

［1］ Thomassen I, van Gestel YR, Lemmens VE, et al. Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin［J］. Dis Colon Rectum, 2013, 56(12): 1373-1380. ［2］陈建林, 宋卫蜂, 陈栋晖. 雷替曲寨治疗晚期大肠癌临床疗效的Mcta分析［J］. 中国新药与临床杂志, 2010, 29(11): 853-857. ［3］ Wang L, Wu Y, Lin L, et al. Metastasisassociated in colon cancer1 upregulation predicts a poor prognosis of gastric cancer, and promotes tumor cell proliferation and invasion［J］. Int J Cancer, 2013, 133(6): 1419-1430. DOI: 10.1002/ijc.28140. ［4］ Hagner N, Joerger M. Cancer chemotherapy: targeting folic acid synthesis［J］. Cancer Manag Res, 2010, 2: 293-301. DOI: 10.2147/CMR.S10043. ［5］ Jarmua A. Antifolate inhibitors of thymidylate synthase as anticancer drugs ［J］. Mini Rev Med Chem, 2010, 10(13): 1211-1222. ［6］ Votanopoulos KI, Swett K, Blackham AU, et al. Cytoreductivesurgery with hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from rectal cancer［J］. Ann Surg Oncol, 2013, 20(4): 1088-1092. DOI: 10.1245/s10434-012-2787-3. ［7］ Elias D, El Otmany A, Bonnay M, et al. Human pharmacokinetic study of heated intraperitonealoxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis［J］. Oncology, 2002, 63(4): 346-352. ［8］曾良玉, 刘运山, 龚晓松, 等. 腹腔化疗预防结直肠癌术后肝转移及局部复发的临床观察［J］. 中国肿瘤临床与康复, 2004, 11(1): 74-75. DOI: 10.3969/j.issn.1005-8664.2004.01.033. ［9］ Cavaliere F, De Simone M, Virzì S, et al. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O.［J］. Eur J Surg Oncol, 2011, 37(2): 148-154. DOI: 10.1016/j.ejso.2010.10.014. ［10］姜海毅, 丁红光, 田晓卫, 等. 术中氟尿嘧啶植入剂腹腔化疗在局部进展期胃癌中的应用［J］. 中华肿瘤防治杂志, 2012, 19(15): 1166-1168. ［11］ Tanner EJ, Black DR, Zivanovic O, et al. Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage ⅢC ovariancancer［J］. Gynecol Oncol, 2012, 124(1): 59-62. DOI: 10.1016/j.ygyno.2011.09.011. ［12］ Ceelen W,De Somer F, Van Nieuwenhove Y, et al. Effect of perfusion temperature on glucose and electrolyte transport during hyperthermic intraperitoneal chemoperfusion(HIPEC) with oxaliplatin［J］. Eur J Surg Oncol, 2013, 39(7): 754-759. DOI: 10.1016/j.ejso.2012.07.120. ［13］ Hompes D, D′Hoore A, Van Cutsem E, et al. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal preoperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase Ⅱ clinical study［J］. Ann Surg Oncol, 2012, 19(7): 2186-2194. ［14］ Tsavaris N, Kosmas C, Vadiaka M, et al. Raltitrexed (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study［J］. Invest New Drugs, 2002, 20(1): 133-136. DOI: 10.1023/A:1014494503230. ［15］ Hind D, Tappenden P, Tumur I, et al. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation［J］. Health Technol Assess, 2008, 12(15): iii-iix, xi-162. ［16］ Cocconi G, Cunningham D, Van Cutsem E, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus highdose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group［J］. J ClinOncol, 1998, 16(9): 2943-2952. ［17］ Khouri C, Guiu B, Cercueil JP, et al. Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study［J］. Anticancer Drugs, 2010, 21(6): 656-661. DOI: 10.1097/CAD.0b013e328337d469. ［18］覃金莲, 陆永奎, 刘莎, 等. 雷替曲塞对比5氟尿嘧啶一线治疗晚期结直肠癌疗效和不良反应的Meta分析［J］. 中国现代医学杂志, 2013, 23(14): 84-90.

[1]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[5]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[6]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[7]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.
[8]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[9]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[10]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273.
[11]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[12]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[13]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722.
[14]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687.
[15]	Wang Xi, Wu Chuanqing. Research progress in reversing multidrug resistance in colorectal cancer [J]. Journal of International Oncology, 2023, 50(1): 42-46.